Long treatment times, poor drug compliance, and natural selection
during treatment of Mycobacterium tuberculosis (Mtb) have given rise to extensively drug-resistant tuberculosis
(XDR-TB). As a result, there is a need to identify new antituberculosis
drug targets. Mtb GlgE is a maltosyl transferase
involved in α-glucan biosynthesis. Mutation of GlgE in Mtb increases the concentration of maltose-1-phosphate (M1P),
one substrate for GlgE, causing rapid cell death. We have designed
2,5-dideoxy-3-O-α-d-glucopyranosyl-2,5-imino-d-mannitol (9) to act as an inhibitor of GlgE.
Compound 9 was synthesized using a convergent synthesis
by coupling thioglycosyl donor 14 and 5-azido-3-O-benzyl-5-deoxy-1,2-O-isopropylidene-β-d-fructopyranose (23) to form disaccharide 24. A reduction and intramolecular reductive amination transformed
the intermediate disaccharide 24 to the desired pyrolidine 9. Compound 9 inhibited both Mtb GlgE and a variant of Streptomyces coelicolor (Sco) GlgEI with Ki = 237 ±
27 μM and Ki = 102 ± 7.52 μM,
respectively. The results confirm that a Sco GlgE-V279S
variant can be used as a model for Mtb GlgE. In conclusion,
we designed a lead transition state inhibitor of GlgE, which will
be instrumental in further elucidation of the enzymatic mechanism
of Mtb GlgE.